Pediatric Targeted Therapy denied as duplicate or overlapping therapy by Blue Cross Blue Shield?

Blue Cross Blue Shield's specific coverage criteria for pediatric targeted therapy are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why BCBS Denied This Claim — and Why You Can Appeal

A "duplicate therapy" denial from BlueCross BlueShield for a pediatric targeted therapy typically means BCBS has identified another agent — either already approved on the child's plan or currently being dispensed — that it considers therapeutically equivalent or interchangeable. In pediatric oncology and rare-disease targeted therapy, this framing is frequently incorrect: targeted therapies work through distinct molecular mechanisms tied to specific biomarkers, mutations, or pathways, and two agents in a related class are often not clinically interchangeable for a specific pediatric patient. The appeal should directly address the molecular and clinical distinction between the prescribed therapy and whatever agent BCBS considers duplicative.

## Your Federal Appeal Rights

• Internal appeal (ERISA §503 / ACA §2719): Submit a written internal appeal within the deadline on the denial notice. BCBS must conduct a full-and-fair review that includes evaluation by a clinician with relevant pediatric expertise.
• External review (ACA §2719): After final internal denial, file with an independent external review organization. The window is typically approximately four months from the final internal denial.
• Expedited review: In pediatric oncology and serious pediatric illness, expedited review is almost always appropriate. Request it explicitly; expedited decisions are generally required within 72 hours.
• State insurance department: BCBS licensure varies by state; your state's insurance commissioner may have jurisdiction over utilization review decisions if your plan is not self-funded under ERISA.

## Documentation to Gather

1. Biomarker and molecular testing reports — pathology, genetic, or genomic reports confirming the specific alteration or target that the prescribed therapy addresses. 2. Prescriber's medical-necessity letter — the treating pediatric specialist should explain the distinct mechanism of the prescribed agent relative to the agent BCBS considers duplicative, and why they are not interchangeable for this child's specific diagnosis. 3. Diagnosis and treatment history — full oncology or specialty chart notes documenting prior treatments, response, and current clinical status. 4. FDA prescribing labels for both agents — highlight the differences in labeled indications, mechanisms, and target populations. 5. Applicable pediatric guideline reference — cite the relevant guideline organization (e.g., COG, NCCN Pediatric) generically in support.

## Criteria-Mapping Structure for Your Appeal Letter

| BCBS duplicate-therapy basis | Your response | |---|---| | Other agent deemed equivalent | FDA label comparison showing distinct mechanism/indication | | Same drug class | Prescriber explanation of molecular targeting differences | | No documented clinical distinction | Biomarker report + prescriber letter specific to this child |

The appeal should conclude by requesting that BCBS identify in writing the specific clinical or pharmacological basis for considering the two agents duplicative, and provide the name and specialty of the reviewing clinician.